News & CommentBiomedical Funding

FDA Scientists Resist Cuts in In-House Research Positions

See allHide authors and affiliations

Science  13 Feb 1998:
Vol. 279, Issue 5353, pp. 976-977
DOI: 10.1126/science.279.5353.976

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Nearly one-third of the research job slots at the Food and Drug Administration's (FDA's) Center for Biologics Evaluation and Research (CBER), which combines research with regulation, are slated to disappear over the next 2 years because the FDA has promised not to draw on pharmaceutical industry "user fees" to fund them. Faced with that dire prospect, some CBER scientists are trying to recruit support in Congress, and others are appealing to outside scientists for help. At stake, the CBER scientists say, is the safe and efficient regulation of products such as vaccines and cell-derived proteins, the biological therapeutics that are at the heart of the biotech revolution.